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A B S T R A C T
Background: Pre-treatment HIV-drug-resistance (PDR) to WHO-recommended 1st-line non-nucleoside
reverse transcriptase inhibitors (NNRTI)-based antiretroviral treatment (ART) is increasing in low-resource
communities. We evaluated the risk of PDR on treatment failure if detected at single or multiple codons, at
minority (29%) or higher (10%) frequencies during efavirenz- vs. nevirapine-ART.
Methods: We conducted a pooled analysis across three cohorts of Kenyans initiating 1st-line NNRTI-ART
between 2006 and 2014. Mutations K103N, Y181C, G190A, M184V and K65R were detected by an oligonucle-
otide ligation assay (OLA) and confirmed by Sanger and next-generation sequencing (NGS). PDR was defined
as detection of any mutation by OLA when confirmed by NGS. Treatment failure, defined as plasma HIV RNA
400 copies/mL at month-12 of ART, was compared by PDR genotypes.
Findings: PDR was detected in 59/1231 (4¢8%) participants. Compared to wild-type genotypes, PDR in participants
prescribed nevirapine-ART was associated with increased treatment failure [PDR 69¢2% (27/39) vs. wild-type
10¢4% (70/674); p = 0¢0001], whether detected as minority [66¢7% (4/6)] or higher [69¢7% (23/33)] frequencies in
an individual’s HIV quasispecies (p = 0¢002 and p< 0¢0001, respectively), or mutations at single [50¢0% (12/24)] or
multiple [100¢0% (15/15)] codons (p < 0¢0001). During efavirenz-ART, PDR was also associated with increased
virologic failure [PDR 25¢0% (5/20) vs. wild-type 5¢0% (25/498); p = 0¢005], but only if detected at multiple drug-
resistant codons [50¢0% (3/6); p = 0¢003] or high frequencies PDR [33¢3% (5/15); p = 0¢001].
Interpretation: The risk that PDR confers for treatment failure varies by number of mutant codons and their fre-
quency in the quasispecies, with a lower risk for efavirenz- compared to nevirapine-based regimens. PDR detec-
tion andmanagement could extend the effective use of efavirenz-ART in low-resource settings.
Funding: NIH, PEPFAR.
© 2019 Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license.
(http://creativecommons.org/licenses/by-nc-nd/4.0/)
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1. Introduction
Increased worldwide access to antiretroviral therapy (ART) over
the past two decades has diminished deaths due to infection with
human immunodeficiency virus type-1 (HIV) in low- and medium-
income countries. In 2010, the WHO recommended 1st-line-ART for
HIV-infected adults include either nevirapine (NVP) or efavirenz
(EFV) in combination with zidovudine (ZDV) or tenofovir (TDF) and
lamivudine or emtricitabine (XTC). Given improved outcomes with
EFV- compared to NVP-based ART regimens in multiple observa-
tional studies, [1,2] in 2013, the WHO narrowed their recommenda-
tions to EFV+TDF+XTC. A rising prevalence of pre-ART drug
resistance (PDR), primarily to non-nucleoside reverse transcriptase
inhibitors (NNRTI), [3] raises concern that resistant strains could
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compromise the effectiveness of ART programs. To address this con-
cern the WHO recommends surveillance of antiretroviral (ARV)-
naïve individuals for PDR, and when rates reach 10% that ART pro-
grams implement either testing for PDR prior to initiating ART to
guide the choice of ARV, or a programmatic switch of 1st-line ART
from NNRTI-based to a non-NNRTI-based ART regimen [4].
WHO recommendations do not address the implications of specific
PDR genotypes on the outcome of EFV+TDF+XTC. The risk conferred by
specific genotypes has been ascribed through a combination of in vitro
studies and clinical associations [5]. This study of Kenyans initiating
1st-line NNRTI-ART provides novel insights into differences in the risks
of PDR on virologic treatment failure during NVP- compared to EFV-
based ART, including the risks conferred by specific single and combi-
nations of mutant codons, as well as insights into the risks from PDR
detected as minority frequency variants within an individual’s HIV
quasispecies. Refinements of the risk due to specific mutant codons on
EFV+TDF+XTC are relevant to public health officials’ interpretation of
PDR surveillance data and to clinicians’ management of HIV-infected
individuals’ treatments.
2. Methods
2.1. Study populations
This analysis includes data from Kenyans qualifying to initiate 1st-
line NNRTI-based ART based on local guidelines at Coptic Hope Cen-
ter’s HIV Clinics and who enrolled in studies in 2006, 2010 or 2013/4.
The 2006 Cohort included adults randomized to counseling and/or
pager interventions to enhance ART-adherence, with specimens ret-
rospectively evaluated for the effect of PDR on virologic outcome [6].
The 2010 Cohort included ARV-naïve or single dose-NVP-experi-
enced women enrolled in an observational study of PDR on virologic
outcome [7]. The 2013/4 Cohort included individuals >2 years of age
enrolled into a randomized-control-trial evaluating testing for PDR to
guide the selection of ART regimen on virologic failure (Clinicaltrials.
gov NCT01898754) [8]. Review boards for protection of human sub-
jects at participating institutions approved each study.
2.2. ART regimens and testing of plasma HIV RNA levels and virologic
outcome
Participants received NNRTI-based ART supplied by the President’s
Emergency Plan for AIDS Relief (PEPFAR). Except individuals with PDR
in the 2013/4 study’s intervention arm received 2nd-line protease
inhibitor (PI)-based ART, and these participants are excluded from this
analysis. PEPFAR provided a fixed-dose-combination of stavudine (d4T),
lamivudine (3TC) and NVP in 2006; ZDV or d4T, 3TC and NVP or EFV in
2010; and ZDV or TDF, 3TC and NVP or EFV in 2013/4. Demographic
and clinical information were collected from medical records, and
plasma HIV RNA viral load (VL) tests were performed at enrollment and
subsequent time-points, including month-12 of ART. This analysis
includes all participants from the three cohorts who initiated NNRTI-
based ART and had month-12 virologic outcome, with virologic failure
defined as VL400 copies/mL at month-12 of ART.
2.3. HIV drug resistance testing
Pre-ART plasma (2006 and 2010) and PBMC (2010 and 2013/4)
were screened for drug resistance by an oligonucleotide ligation assay
(OLA) sensitive to 2% mutant within a participant’s viral population
[9]. The OLA detected mutations conferring high-level resistance to
NVP/EFV (K103N, Y181C, G190A), 3TC (M184V) and beginning in 2010
to TDF (K65R) using probes optimized for HIV type-1 subtypes A, D
and C. The OLA also quantified the frequency of these mutations in the
individual’s HIV quasispecies. The primary analysis only included the
plasma OLA results from the 2010 cohort, except when plasma results
were not available PBMC results were used (n = 10/169). Pre-ART
specimens with mutations detected by OLA and/or with virologic fail-
ure were evaluated for additional mutations by Sanger consensus
sequencing and next-generation-sequencing (NGS) by either 454-
pyrosequencing [6,9] or Illumina assays [10]. Plasma specimens from
the time of virologic failure were genotyped by Sanger sequencing and
OLA. To minimize reporting of potential false positive OLA near the
limit of detection, mutations detected at low frequencies by OLA
(<25% of an individual’s HIV population) were included in the primary
analysis when confirmed by NGS at a mutant frequency of 1%, while
all mutations detected by OLA, including those not confirmed by NGS,
were included in a sensitivity analysis. Sequences are available in
Research in context
Evidence before this study
Increasing pretreatment HIV drug resistance (PDR) to non-
nucleoside reverse transcriptase inhibitors (NNRTI) has
attained prevalences 10% in many low- and lower-middle
income countries. This led the World Health Organization to
recommend that programs switch 1st-line antiretroviral ther-
apy (ART) from efavirenz- to dolutegravir-based ART. Past stud-
ies reporting that PDR increases the risk of virologic failure
during NNRTI-ART often combined data from nevirapine or efa-
virenz combined with zidovudine or stavudine and lamivudine.
We searched PubMed for articles published in English from
1995 through December 2018 with the terms “nevirapine ver-
sus efavirenz” and “first-line ART” OR “initial ART”, “pretreat-
ment HIV drug resistance” OR “minority drug resistant
variants” OR “low-frequency drug resistant variants” AND
“treatment failure” OR “virologic failure”, and reviewed data
from scientific conferences. A recent trial (ANRS 12249) found
that PDR did not increase rates of virologic failure with an efa-
virenz+tenofovir+emtricitabine regimen, suggesting that PDR
has a lesser risk of virologic failure with this regimen.
Added value of this study
This pooled analysis is unique in examining the risk of PDR in a
large group of Kenyans initiating 1st-line nevirapine- or efavir-
enz-based ART within a single clinic system, and provides novel
insights into differences in the risks of specific HIV drug resis-
tance mutations on virologic treatment failure during nevira-
pine- compared to efavirenz-based ART. We found that
tenofovir+lamivudine+efavirenz had superior virologic out-
comes compared to nevirapine-based regimens, including
among ARV-naïve or ARV-experienced individuals and those
with wild-type virus or PDR; and while the most common
NNRTI mutation, K103N, when detected as a single mutation
increased virologic failure with nevirapine-based-ART, it did
not increase virologic failure with tenofovir+lamivudine
+efavirenz.
Implications of all the available evidence
Defining the risk that specific mutant codons confer to tenofo-
vir+lamivudine/emtricitabine (XTC)+efavirenz is relevant for
public health officials’ interpretation of PDR surveillance data
and for clinicians’ management of HIV-infected individual’s
treatment. In spite of rising rates of PDR, use of the tenofovir
+XTC+efavirenz combination as 1st-line ART could be effective
in settings not ready to adopt implementation of dolutegravir-
based ART, in subpopulations where it is contraindicated, or in
individuals who do not tolerate dolutegravir-based ART.
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GenBank (accession # KF544089-KF544288, KJ395348-KJ395349,
MH509760-MH509936, MK512771-MK513407).
2.4. Statistical analysis
Comparisons between cohorts and enrollment characteristics were
made using KruskalWallis test for continuous variables and as appro-
priate by Chi-square or Fisher’s exact test for proportions. Differences
in virologic failure at months-6 or 8 and month-12 were compared
using Fisher’s Exact or Chi-square test, as appropriate. Poisson regres-
sion models with robust standard errors were used to determine inci-
dence rate ratios (IRR) and 95% confidence intervals (CI) to examine
characteristics associated with virologic failure at 12-months. We
determined a priori to adjust our models for viral load at ART initiation
and study cohort due to known associations of these factors with use
of NVP vs. EFV-based ART and virologic failure outcomes. Additional
covariates associated with virologic failure at P  0.05 were included
in multivariable analysis. Statistical analyses were performed using
Stata 14 (Stata Corporation, College Station, Texas).
This manuscript adheres to STROBE guidelines for cohort studies.
3. Results
3.1. Study population characteristics
Among the three cohorts, a total of 1385 participants had PDR
testing prior to initiating NNRTI-based ART. A total of 1231 (89%)
participants were followed through 12 months of ART and were
assessed for virologic failure or suppression during this 12-month
time interval. Differences between the three cohorts include: (1)
the 2010 Cohort was exclusively women with ~50% having taken
ARV prophylaxis for prevention of mother-to-child transmission
(PMTCT) which was associated with higher prevalence of PDR; (2)
the median VL progressively decreased with more recent year of
enrollment; (3) the median CD4 count of each more recent cohort
increased from 123 to 165 to 235 cells/mL (p = 0¢0001); and (4) the
NNRTI shifted from 100% of participants prescribed NVP-based ART
in 2006, to 85% in 2010, to 35% in 2013/4, replaced by efavirenz.
Similarly, the NRTIs shifted from d4T to ZDV to TDF, all combined
with 3TC (Table 1).
3.2. Pre-antiretroviral-treatment drug resistance (PDR)
Participants in the 2013/4 Cohort intervention arm were excluded
from this study if PDR was detected and participant was prescribed
PI-based ART. An additional 9 participants with PDR detected at fre-
quencies <9% by OLA (median 2%, range 24%) were classified as
wild-type for the primary analysis as their mutations were not con-
firmed by NGS.
In the primary analysis PDR was detected by OLA and confirmed by
NGS in 59/1231 (4¢8%, 95% CI, 3¢73 to 6¢14) participants at a median
mutant frequency of 83% (range 2100%, IQR 16100%). Among 1079
ARV-naïve participants the prevalence of PDR was 4¢1% (95% CI, 3¢04 to
5¢44) with a median mutant frequency of 81% (range 3100%, IQR
1698%), and among the 144 ARV-experienced, PDR prevalence was
higher (9¢7%, 95% CI, 5¢7715¢77; p < 0¢0001), but the median mutant
frequency was similar (93%; range 2100%, IQR 20100%). Among the
59 participants with PDR, NNRTI mutations (K103N, Y181C, G190A)
were detected in all but one (98¢3%) and NRTI mutations (K65R,
M184V) were detected in 14 (23¢7%). Single NNRTI mutations were
detected in 37 (62¢7%), with K103N most frequently detected (30/59,
50¢8%), multiple NNRTI mutations were detected in 8 (13¢6%), and mul-
tiple NNRTI/NRTI mutations in 13 (22¢0%). A single NRTI mutation was
detected in one (1¢7%) participant.
Table 1
Population characteristics and month-12 virologic outcome among subjects by 1st-line ARV regimen and pre-ART genotype across three Kenyan cohorts.
Variable Total Study 2006 Study 2010 Study 20132014 P-value
N with month-12 outcome 1231 303 169 759a
Age (years), median (IQR) 36 (3044) 36 (3143) 33 (2938) 38 (3145) 0.0001b
Female, N (%) 870 (70¢7) 202 (66¢7) 169 (100¢0) 499 (65¢7) <0.0001e
CD4 count (cells/mL), median (IQR) 186 (102278) 123 (65180) 165 (116233) 235 (132316) 0.0001b
Pre-ART VL (log10 c/mL), median (IQR) 4.95 (4.235.55) 5.66 (5.226.02) 4.90 (4.355.32) 4.66 (3.935.20) 0.0001b
NVP or EFV-ART, N (%) <0.0001c
NVP-ART 713 (57.9) 303 (100.0) 144 (85.2) 266 (35.0)
d4T-3TC 330/713 (46.3) 303/303 (100.0) 27/144 (18.8) 0/266 (0.0)
ZDV-3TC 219/713 (30.7) 0/303 (0.0) 109/144 (75.7) 110/266 (41.4)
TDF-3TC 154/713 (21.6) 0/303 (0.0) 8/144 (5.6) 146/266 (54.9)
ABC-3TC 10/713 (1.4) 0/303 (0.0) 0/144 (0.0) 10/266 (3.8)
EFV-ART 518 (42.1) 0 (0.0) 25 (14.8) 493 (64.9)
TDF-3TC 486/518 (93.8) 0 (0.0) 1/25 (4.0) 485/493 (98.4)
ZDV/d4T/ABC-3TC 32/518 (6.2) 0 (0.0) 24/25 (96.0) 8/493 (1.6)
PDR at enrollment, N (%) All participants 59 (4.8) 8 (2.6) 17 (10.1) 34d (4.5) 0.0010e
ARV-naïve 44/1079 (4.1) 8/303 (2.6) 6/97 (6.2) 30/679f (4.4) 0.234e
ARV-experiencedg 14/144 (9.7) 0/0 (0.0) 11/72 (15.3) 3/72f (4.2) 0.046c
VF 400c/mL, N (%) All participants 127 (10.3) 24 (7.9) 38 (22.5) 65 (8.6) <0.0001e
Wild-type 95/1172 (8.1) 19/295 (6.4) 26/152 (17.1) 50/725 (6.9) <0.0001e
Mutant 32/59 (54.2) 5/8 (62.5) 12/17 (70.6) 15/34 (44.1) 0.178 e
ARV-naïve 102/1079 (9.5) 24/303 (7.9) 17/97 (17.5) 61/679 (9.0) 0.015 e
ARV-experienced 24/144 (16.7) 0/0 (0.0) 21/72 (29.2) 3/72 (4.2) <0.0001c
Abbreviations: ARV, antiretroviral; ART, antiretroviral therapy; IQR, interquartile range; VL, plasma HIV RNA level; NVP, nevirapine; EFV, efavirenz; d4T, stavu-
dine; 3TC, lamivudine; ZDV, zidovudine; TDF, tenofovir; ABC, abacavir; PDR, pre-ART drug resistance; VF, virologic failure.
a Excludes 44 subjects who were prescribed 1st-line PI-ART, 35 due to PDR diagnosed by OLA and nine switched to PI-ART due to clinical indications.
b Kruskal Wallis test.
c Fisher’s Exact test.
d Total PDR at enrollment of parent study was 8.7% (70/803) including 36 subjects with drug resistance who were prescribed PI-ART, and excluded from this
analysis.
e Chi-square.
f 8 subjects missing drug exposure information.
g ARV-experienced denotes participants receiving ARV prophylaxis for prevention of mother-to-child transmission.
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3.3. PDR and virologic outcome during 12 months of NNRTI-ART
Virologic failure occurred in 127 of 1231 (10¢3%) participants, and
occurred at a greater rate in those prescribed NVP-ART compared to
EFV-ART (13¢6% vs. 5¢8%, p < 0¢0001), including those with wild-type
virus, PDR, ARV-naïve and ARV-experienced (Table 2). The rates of
virologic failure with NVP combined with 3TC and ZDV, d4T or TDF
regimens were all higher than with EFV+3TC+TDF ART (p < 0¢0001;
Table A1, Appendix). In multivariable analysis adjusting for cohort,
enrollment VL, and NRTI type, participants receiving EFV+3TC+TDF
had a lower risk of virologic failure compared to those receiving NVP-
based ART regimens (adjusted Incident Rate Ratio, IRR: 0¢3, 95% CI
0¢10¢7; p = 0¢008). The proportion that experienced virologic failure
by month-6 or 8 of ART was higher in those with vs. without PDR
[93¢7% (30/32) vs. 62¢8% (54/86), p = 0¢0006].
When compared to participants with wild-type viruses, those
who only harbored minority variants, either 29% by OLA or detected
by OLA but missed by Sanger sequencing (median 5%, range 225%,
IQR 411%), had an increased rate of virologic failure when pre-
scribed NVP-ART but not EFV-ART (Table 2). (NOTE: Sensitivity analy-
sis including the 9 participants with mutations at frequencies of
29% by OLA, but not confirmed by NGS showed similar results; par-
ticipants with minority variants prescribed NVP-ART had signifi-
cantly higher rate of virologic failure compared to those with WT
[60% (6/10) vs. 10¢4% (68/670), p = 0¢0002], but those with minority
variants prescribed EFV-ART had rates of virologic failure similar to
WT [10% (1/10) vs. 5% (24/493), p = 0¢402]). Among participants tak-
ing NVP-ART, those with a single K103N or multiple NNRTI/NRTI
mutations had higher rates of virologic failure compared to those
with no PDR mutations (Table 2). In contrast, among participants
taking EFV-ART only those with multiple mutations had increased
rates of virologic failure compared to those with wild-type genotype,
and those with only K103N had rates of virologic failure similar to
those with wild-type HIV (Table 2).
An increase in the composite parameter “mutant load” (VL x
mutant frequency) was associated with an increased risk of virologic
failure among participants with PDR (median mutant load 2021 vs.
35,428 copies/mL, p = 0¢0032), including those with single Y181C,
M184V or G190A mutations, and those with multiple NNRTI/NRTI
mutations, but not among those with single K103N mutations
(Table 3). Effects of mutant load by drug-regimen could not be evalu-
ated due to insufficient prevalence of specific mutations.
Poisson regression models compared virologic failure among par-
ticipants treated with NVP- vs. EFV-based-ART adjusting for parame-
ters significantly associated with treatment failure, including, CD4
T-cells counts, pre-ART VL, cohort, and PDR (data not shown). The
model that best fit the data (Table A2, Appendix) showed indepen-
dent effects of VL, PDR, cohort and ART regimen on virologic failure:
EFV-based ART was associated with a significantly lower risk for viro-
logic failure (IRR 0¢43, 95% CI 0¢280¢66; p < 0¢0001) compared to
NVP-based ART; higher VL at enrollment was associated with higher
risk of virologic failure (IRR 1¢19, 95% CI 1¢091¢29; p < 0¢0001); PDR
2% was associated with a 5-fold increased risk of virologic failure
(IRR 5¢38, 95% CI, 3¢947¢35, p < 0¢0001); and participation in the
2010 and 2013/14 Cohort with higher IRR for virologic failure (3¢26,
95% CI 1¢985¢35; p < 0¢0001 and 2¢42, 95% CI, 1¢464¢02,
p = 0¢0010, respectively). These associations remained with inclusion
or exclusion of prior nevirapine (single dose) for prevention of
mother-to-child transmission as a covariate in the multivariable
model.
Table 2
Rates of virologic failure at month-12 of NVP- vs. EFV-ART by OLA/NGS-detected drug resistance at 5 HIV pol RT codons (K65R,
K103N, Y181C, M184V and G190A) and other factors at enrollment.
NVP-ART EFV-ART
Variable N N VF % VF p-valuea N N VF % VF p-valuea
NVP vs. EFV
p-valuea
Total participants 713 97 13.6 518 30 5.8 <0.0001b
ARV-naïvec 614 76 12.4 465 26 5.6 0.0001b
ARV-experienced c 99 21 21.2 45 3 6.7 0.031
Wild-type 674 70 10.4 Reference 498 25 5.0 Reference 0.0008
ARV-naive 587 56 9.5 448 21 4.7
ARV-experienced 87 14 16.1 43 3 7.0
Any mutants (2%) 39 27 69.2 <0.0001 20 5 25.0 0.0049 0.0021
ARV-naive 27 20 74.1 17 5 29.4
ARV-experienced 12 7 58.3 2 0 0.0
29% mutantd 6 4 66.7 0.0016 5 0 0.0 1.000 NA
ARV-naive 5 4 80.0 4 0 0.0
ARV-experienced 1 0 0.0 0 0 0.0
10% mutant 33 23 69.7 <0.0001 15 5 33.3 0.0014 NA
ARV-naive 22 16 72.7 13 5 38.5
ARV-experienced 11 7 63.6 2 0 0.0
OLA (+); CS () 10 5 50.0 0.0023 6 0 0.0 1.000 NA
ARV-naive 8 5 62.5 4 0 0.0
ARV-experienced 2 0 0.0 1 0 0.0
OLA (+); CS (+) 29 22 75.9 <0.0001 14 5 35.7 0.0007 NA
ARV-naive 19 15 78.9 13 5 38.5
ARV-experienced 10 7 70.0 1 0 0.0
Single K103N 20 9 45.0 0.0001 10 1 10.0 0.412 NA
Single Y181C, G190A or M184V 4 3 75.0 0.0044 4 1 25.0 0.192 NA
Multiple NNRTI/NRTI 15 15 100.0 <0.0001 6 3 50.0 0.0028 NA
Abbreviations: NVP, nevirapine; EFV, efavirenz; ART, antiretroviral therapy; VF, virologic failure (plasma HIV RNA >400 copies/mL);
ARV, antiretroviral; OLA, oligonucleotide ligation assay; CS, consensus sequencing; NA, not applicable; NNRTI, non-nucleoside
reverse transcriptase inhibitor; NRTI, nucleoside reverse transcriptase inhibitor.
a Fisher's exact.
b Chi-square test.
c Excludes 8 participants in the EFV-ART group without data for history of ARV exposure.
d Sensitivity analysis including participants with mutations detected by OLA at frequencies 29% that were not confirmed by
NGS: 6/10 (60%) had VF on NVP-ART vs. 1/10 (10%) on EFV-ART, p = 0.057.
Note: NA, not applicable, due to small sample size.
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3.4. Drug resistance at virologic failure
Genotypic Sanger sequencing and OLA of virologic failure speci-
mens was completed for 125 and 126 of 127 participants, respec-
tively. Sanger sequencing revealed wild-type in 27 (21¢6%) and drug
resistant mutations (DRM) in 98 (78¢5%). These included 32/127
(25¢2%) participants with PDR. Most with PDR maintained these
same DRM at virologic failure (23/32; 71¢9%), either with (18/32;
56¢3%) or without (5/32; 15¢6%) additional DRM. Different genotypes
were detected in the remainder, either different DRMs (7/32; 21¢9%)
or wild-type (2/32; 6¢3%). PDR minority variants (<10%) by OLA were
detected less frequently at virologic failure compared to DRM 10%
(40¢0% vs. 90¢9%, p = 0¢0013). At virologic failure, DRM were detected
more frequently among the 32 with PDR compared to the 94 partici-
pants with wild-type genotype at enrollment (93¢7% vs. 72¢3%,
p = 0¢013); with prevalences shown in Table A3 (Appendix). Preva-
lence of DRM at virologic failure was not significantly different
among participants taking NVP-ART vs. EFV-ART (79¢2% vs. 73¢3%,
p = 0¢615). OLA testing of virologic failure plasma specimens detected
DRMs in 104/126 (82.5%). Among the 125 participants with Sanger
sequencing at virologic failure, 24 had resistance mutations to AZT,
d4T or abacavir at codons not tested by the OLA. In addition, the OLA
did not detect resistance to NNRTI in one participant with V106M
and Y188C, or resistance to 3TC in four participants with M184I, as
these mutations were not interrogated by the OLA. However, OLA of
plasma at virologic failure identified all participants with DRM by
Sanger sequencing and detected low-level DRM in six additional par-
ticipants.
4. Discussion
This pooled analysis is unique in examining the outcome of PDR in
a large group of Africans initiating 1st-line NVP- or EFV-based ART
within a single clinic system. Salient observations from the study
include that PDR increases the risk of (1) virologic failure within a
few months of NNRTI-ART initiation; and increases the risk of viro-
logic failure in association with: (2) increased number of mutant
codons; (3) increased frequencies of mutant variants within an indi-
vidual’s HIV quasispecies; and (4) at an increased rate with NVP-
compared to EFV-based ART regimens. We observed that (5) EFV
+3TC+TDF regimens are associated with increased rates of ART-sup-
pression both among ARV-naïve and -experienced individuals; and
(6) that participants with virologic failure by month-12 of ART had
multiple NNRTI and NRTI mutations regardless of whether at enroll-
ment they had PDR or wild-type genotype.
While randomized trials have not found EFV-based-ART regimens
superior to NVP-based ART, [11] multiple observational studies,
[1,2,12,13] in addition to ours, show superior virologic and clinical
outcomes with EFV- compared to NVP-based ART. Our study is novel
in observing that EFV-based ART was more effective than NVP- based
ART in suppressing HIV replication in ARV-naïve individuals with
likely TDR.
A notable observation in our study is that participants with only
the K103N mutation, the most prevalent DRM conferring high-level
of resistance to NNRTI [5], had similar rates of virologic failure com-
pared to those with wild-type genotypes when prescribed EFV+3TC
+TDF, but increased rates of virologic failure with NVP-based ART. A
South African study recently reported that PDR primarily with the
single K103N mutation was not associated with increased rates of
virologic failure during ART with TDF+FTC+EFV [14]. While the same
DRM are associated with HIV resistance to EFV and NVP, EFV is more
potent than NVP in studies of wild-type and drug resistant HIV var-
iants tested in vitro [2,15], and TDF is more potent than AZT and d4T
[16]. In addition, EFV has a longer plasma half-live (4055 h) [17]
compared to NVP (2530 h) [18], and therefore, delayed or missed
EFV doses would be less likely to result in drug levels falling below
the inhibitory concentration. These factors, in addition to improved
adherence that one would expect with the use of a fixed-dose combi-
nation of EFV+XTC+TDF could all contribute to the superior virologic
outcome of this regimen. Single Y181C and G190A mutations
appeared to increase virologic failure with NVP-ART more than EFV-
ART, but the prevalence of these mutations was insufficient for statis-
tical comparison. PDR with NRTI mutations K65R and M184V were
detected infrequently and, except for one participant with a single
M184V, always in combination with NNRTI mutations.
EFV-based-ART in our study appeared more effective than NVP-
based ART among those with minority variant DRM, regardless as to
whether defined as <10% of the HIV quasispecies by OLA or as DRM
detectable by OLA and undetectable by Sanger sequencing. In sdNVP-
exposed women initiating a NVP-based regimen, NNRTI minority var-
iants detected by sensitive assays have been associated with VF [19].
Our 2010 Cohort included women exposed to serial ARV for MTCT
who tended to have more minority variants, including NRTI muta-
tions not assessed by OLA, and when these women were compared
to ARV-naïve women they had increased rates of VF when given
NVP-based ART [7]. Several studies examining the role of minority
variants in treatment outcomes have observed associations with
treatment failure during NNRTI-regimens in treatment-naïve
[2025] and treatment-experienced patients [26], while other stud-
ies, similar to this study, found no association between minority var-
iants detected in ARV-naive African or European patients with
virologic failure of 1st-line EFV-ART [14,2729] or NVP-ART [30].
Some of the aforementioned studies used allele-specific-PCR to
detect K103N alone, or K103N +Y181C [19,20,22,23,26,30]. Other
studies using next generation sequencing found that G190A [25], or
other NNRTI mutations were more prevalent than K103N or Y181C
[21,24,28]. It is possible that NNRTI or NRTI mutations not tested for
contributed to virologic failure.
Several studies of PDR effects on treatment outcomes of ART-
naïve individuals combined different NNRTI or NRTI regimens in their
analyses [2123,2529]. A comparison of the risk of minority var-
iants across regimens observed increased virologic failure with EFV
+ZDV+3TC but not EFV+TDF+FTC [22], similar to our findings. Com-
bined studies suggest that minority variant NNRTI mutations may
vary in the risk of virologic failure by the potency of the regimen,
Table 3
Pre-ART mutant load (viral load x greatest mutant frequency) compared in participants with viral suppression vs. virologic failure at month-12 of
NNRTI-ART.
Viral suppression Virologic failure
Pre-ART mutation N Median (IQR) mutant load copies/mL N Median (IQR) mutant load copies/mL p-value
Any mutation (2%) 27 2021 (67073,463) 32 35,428 (14,480268,908) 0.0032
Single K103N 20 11,790 (1355135,908) 10 23,260 (15,683239,244) 0.202
Single Y181C, G190A or M184V 4 830 (4281325) 4 87,391 (23,726259,812) 0.021
Multiple NNRTI/NRTI 3 552 (460961) 18 57,289 (9966244,671) 0.016
Abbreviations: NNRTI, non-nucleoside reverse transcriptase inhibitor; NRTI, nucleoside reverse transcriptase inhibitor; ART, antiretroviral ther-
apy; IQR, interquartile range.
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specific mutation(s), HIV subtype and/or whether the mutation was
transmitted, selected by past NNRTI or was spontaneously generated
in the host or as an artifact of PCR and/or sequencing.
The effect of minority variants on the risk of virologic failure has
also been associated with the absolute numbers of drug-resistant var-
iants (i.e. mutant load). Using allele-specific-PCR, K103N at levels of
>2000 copies/mL were associated with virologic failure of EFV-ART
[22], others described a dose-dependent risk of virologic failure start-
ing at 1099 copies/mL [20], and a study using next-generation-
sequencing suggested drug-resistant variants at <1000 copies/mL
were not associated with virologic failure of 1st-line NNRTI-ART [29].
In our study, participants with single K103N and virologic suppres-
sion (mostly taking EFV-based ART) had a median mutant load of
11,790 copies/mL, significantly higher than previously described
thresholds for virologic failure. While mutant load might be more
predictive of virologic failure than the frequency of drug-resistant
variants, the failure threshold for different mutations is likely to be
dependent on the potency of the ART regimens.
Compared to Sanger sequencing, the OLA used in this study identi-
fied PDR in all but one participant (with K70R) who subsequently expe-
rienced virologic failure. In addition, OLA identified all participants with
DRM by Sanger sequencing at virologic failure, including several partic-
ipants with drug resistance not detected by Sanger sequencing. An eco-
nomical and easy to use point of care OLA kit that assesses NNRTI
mutations K103N, Y181C, G190A and NRTI mutations M184V and
K65R [31] could be used in resource-limited settings to test patients
prior to starting EFV-based ART, at virologic failure to guide the choice
of 2nd-line ART, or before switching to dolutegravir-based ART.
Limitations of this observational study include the non-random-
ized comparison between NVP- and EFV-based ART regimens and dif-
ferences in inclusion criteria across the three cohorts which increases
the potential for residual confounding variables in the analysis. The
primary differences between the cohorts that may have affected our
findings include the lower median pre-ART plasma RNA viral load
and higher median CD4 count in the 2013/4 Cohort, and that
improved ART adherence was a study objective and likely higher in
the 2006 Cohort in which participants were randomized to interven-
tions aimed at improving ART adherence and were given a fixed dose
combination of d4T+3TC+NVP [6]. However, in regression analysis
controlling for viral load, CD4 counts and cohort, enhanced viral sup-
pression remained associated with EFV-ART. Our 2010 Cohort by
design had a higher proportion of women who took single or sequen-
tial ARV for PMTCT. These women, with higher rates of PDR by OLA,
were more frequently prescribed NVP- compared to EFV-based ART,
which could have enhanced the association between minority var-
iants and more virologic failure associated with NVP-ART. Also, fewer
participants with PDR received EFV-ART, and because relatively few
participants had minority variants by OLA this could have reduced
our ability to detect associations with virologic failure. Because
Sanger sequencing and/or NGS were performed on pre-ART speci-
mens of participants with virologic failure only, our study could not
assess the risk for treatment failure of other PDR mutations not
detected by OLA. Lastly, in this study we considered participants with
mutations at frequencies 29% by OLA that were not confirmed by
NGS as having wild-type genotype. However, rates of virologic failure
were similar in participants with OLA mutations, regardless of
whether confirmed by NGS (4/12 (33¢3%) vs. 3/9 (33¢3%), p = 1¢0), and
both NGS-confirmed and -unconfirmed minority variants were asso-
ciated with increased rates of virologic failure compared to those
with wild-type virus by OLA. This observation suggests that OLA test-
ing may have been more sensitive than NGS, and by discounting
mutations not confirmed by NGS, we slightly inflated the risk of viro-
logic failure among participants analyzed as wild-type by OLA.
In summary, the risk that PDR confers for treatment failure of
NNRTI-based ART varies by specific single and combinations of codons,
and frequency of mutant variants in the individual’s viral quasispecies,
with substantially less virologic failure for EFV+3TC+TDF compared to
NVP-based regimens. These findings suggest that use of assays to
detect and manage PDR could maximize viral suppression and extend
the effective use of EFV-based antiretroviral treatment regimens in
low-resource settings. Despite rising rates of PDR, effectiveness of EFV
+XTC+TDF as 1st-line ART is likely greater than predicted by past stud-
ies that included NVP-based ART regimens. Thus, EFV+XTC+TDF may
retain efficacy in HIV-infected subpopulations where fixed-dose dolu-
tegravir is not approved or contraindicated, such as infants and chil-
dren weighing <30 kg, HIV/TB co-infected individuals, or those who
do not tolerate dolutegravir-based ART.
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